Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Trial Profile

An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2018

At a glance

  • Drugs NEO-PV 01 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Pemetrexed; Poly ICLC
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Neon Therapeutics
  • Most Recent Events

    • 01 Oct 2018 According to a Neon Therapeutics media release, data from the trial will be presented at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting.
    • 31 Aug 2018 Biomarkers information updated
    • 06 Aug 2018 According to a Neon Therapeutics media release, 52-week data is expected in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top